FDA Approves KEYTRUDA®

FDA Approves Merck's Keytruda for First-Line Treatment of Pleural ...

The mesothelioma approval for the Keytruda combination regimen potentially unlocks a $12 billion market opportunity, according to a recent ...

Approved Indications for KEYTRUDA® (pembrolizumab)

KEYTRUDA is indicated for the treatment of patients with unresectable or metastatic MSI⁠-⁠H or dMMR colorectal cancer (CRC) as determined by an FDA-approved ...

FDA Approves Pembrolizumab/Chemoradiation in Stage III/IVA ...

Findings from the phase 3 KEYNOTE-A18 trial support the FDA approval of pembrolizumab plus external beam radiotherapy and concurrent ...

FDA Approval Summary: Pembrolizumab for the Treatment of ...

On August 5, 2016, the FDA granted pembrolizumab accelerated approval for the treatment of patients with recurrent or metastatic HNSCC with disease progression ...

FDA Approves Perioperative Pembrolizumab Plus Chemotherapy in ...

The FDA has approved pembrolizumab in the perioperative setting for resectable stage II, IIIA, or IIIB non–small cell lung cancer.

FDA Approves KEYTRUDA® (pembrolizumab) As Adjuvant ...

Approval based on KEYNOTE-091 trial, which demonstrated a clinically meaningful improvement in disease-free survival with KEYTRUDA in these ...

FDA Approves New Treatment Regimen for Individuals Receiving ...

On October 16, 2023, the U.S. FDA approved a new treatment plan for people receiving Keytruda (pembrolizumab) for resectable NSCLC.

FDA approves pembrolizumab for esophageal or GEJ carcinoma

FDA approved pembrolizumab (Keytruda, Merck Sharp & Dohme Corp.) in combination with platinum and fluoropyrimidine-based chemotherapy for ...

FDA Approves Neoadjuvant/Adjuvant Pembrolizumab for ... - OncLive

The FDA has approved pembrolizumab (Keytruda) in combination with platinum-containing chemotherapy as neoadjuvant treatment, and with ...

FDA Approves Pembrolizumab With Chemotherapy in Advanced ...

The FDA approved pembrolizumab (Keytruda) plus carboplatin and paclitaxel, followed by single-agent pembrolizumab, in adult patients with ...

KEYTRUDA® / Pembrolizumab + Chemo Receives FDA Approval

Mesothelioma: KEYTRUDA® / Pembrolizumab + Chemo Receives FDA Approval · Comments. thumbnail-image. Add a comment...

FDA Approves Keytruda With Chemotherapy to Treat Mesothelioma

Keytruda used in combination with chemotherapy is now an FDA-approved first-line treatment for pleural mesothelioma.

FDA Approves Keytruda® for Lung Cancer

The programmed death (PD-1) inhibitor Keytruda® (pembrolizumab) has been granted approval by the US Food and Drug Administration (FDA) for use in lung ...

FDA Expands Approval of Pembrolizumab for Lung Cancer - NCI

A Cancer Currents blog post on FDA's approval of pembrolizumab (Keytruda®) to be used with chemotherapy as a first-line treatment for ...

FDA Approves Pembrolizumab/Chemo in Unresectable Pleural ...

FDA Approves Pembrolizumab/Chemo in Unresectable Pleural Mesothelioma ... Data from the KEYNOTE-483 trial support the FDA approval of the ...

FDA Approves Pembrolizumab for Treatment of Advanced Melanoma

On February 15, 2019, the US Food and Drug Administration (FDA) approved the immunotherapy agent pembrolizumab (Keytruda; Merck) for the adjuvant treatment ...

FDA approves Keytruda regimen for advanced endometrial cancer

The FDA approved the use of pembrolizumab in combination with chemotherapy for adults with primary advanced or recurrent endometrial ...

FDA approves Keytruda plus chemo for primary advanced, recurrent ...

The U.S. Food and Drug Administration has approved Merck's Keytruda (pembrolizumab) plus chemotherapy as treatment for adult patients with ...

FDA Approves Keytruda Plus Chemotherapy for Biliary Tract Cancer

The approval of pembrolizumab (Keytruda; Merck) combined with gemcitabine and cisplatin for the treatment locally advanced unresectable or ...

FDA approval of Keytruda (pembrolizumab) as adjuvant treatment ...

Listen to a soundcast of the January 26, 2023, FDA approval of Keytruda (pembrolizumab) as adjuvant treatment for non-small cell lung ...